IRIS
RUSSO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.798
NA - Nord America 1.712
AS - Asia 805
SA - Sud America 304
Continente sconosciuto - Info sul continente non disponibili 93
AF - Africa 19
Totale 4.731
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.666
RU - Federazione Russa 891
SG - Singapore 312
PL - Polonia 281
BR - Brasile 266
CN - Cina 225
IE - Irlanda 177
SE - Svezia 135
IT - Italia 125
HK - Hong Kong 85
FR - Francia 80
VN - Vietnam 52
IN - India 27
DE - Germania 25
CA - Canada 22
FI - Finlandia 19
ID - Indonesia 18
BE - Belgio 16
AR - Argentina 14
BD - Bangladesh 14
UA - Ucraina 12
GB - Regno Unito 11
TR - Turchia 8
CO - Colombia 7
MX - Messico 7
PH - Filippine 7
UZ - Uzbekistan 7
IQ - Iraq 6
JP - Giappone 6
ZA - Sudafrica 6
EC - Ecuador 5
PK - Pakistan 5
AE - Emirati Arabi Uniti 4
AT - Austria 4
ES - Italia 4
IL - Israele 4
JM - Giamaica 4
KR - Corea 4
MY - Malesia 4
NL - Olanda 4
VE - Venezuela 4
AL - Albania 3
HN - Honduras 3
NP - Nepal 3
OM - Oman 3
AO - Angola 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
CW - ???statistics.table.value.countryCode.CW??? 2
EG - Egitto 2
GT - Guatemala 2
KE - Kenya 2
KG - Kirghizistan 2
LT - Lituania 2
PE - Perù 2
PY - Paraguay 2
SA - Arabia Saudita 2
SC - Seychelles 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BS - Bahamas 1
CL - Cile 1
DZ - Algeria 1
EE - Estonia 1
EU - Europa 1
GE - Georgia 1
GY - Guiana 1
IR - Iran 1
JO - Giordania 1
MD - Moldavia 1
MN - Mongolia 1
MZ - Mozambico 1
NI - Nicaragua 1
NO - Norvegia 1
PA - Panama 1
PT - Portogallo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
Totale 4.641
Salva come PNG Salva come JPEG
Città #
Ashburn 303
Warsaw 278
Moscow 245
Dublin 177
Chandler 168
Singapore 159
Dallas 93
Hong Kong 85
San Jose 82
Beijing 74
Nyköping 68
New York 48
Council Bluffs 46
Messina 46
Ann Arbor 43
The Dalles 43
Princeton 36
Jacksonville 35
Dearborn 34
Los Angeles 29
Lauterbourg 27
Medford 27
Des Moines 26
Dong Ket 18
Cambridge 17
Brussels 16
Fort Washington 14
São Paulo 14
Wilmington 14
Buffalo 13
Ho Chi Minh City 13
Chicago 12
Houston 12
Jakarta 11
Jinan 11
Tianjin 11
Munich 10
Santa Clara 10
Belo Horizonte 8
Chennai 8
Guangzhou 8
Hanoi 8
Redondo Beach 8
Shenyang 8
Toronto 8
Woodbridge 8
Boardman 7
Falls Church 7
San Mateo 7
Seattle 7
Stockholm 7
Tashkent 7
Atlanta 6
Brooklyn 6
Hillsboro 6
Pune 6
San Francisco 6
Curitiba 5
Hebei 5
Nanjing 5
Newark 5
Orem 5
Rio de Janeiro 5
Tokyo 5
Anagni 4
Brasília 4
Cagliari 4
Columbus 4
Dhaka 4
Dongdaemun-gu 4
Fairfield 4
Juiz de Fora 4
London 4
Mexico City 4
Milan 4
Mumbai 4
Nanchang 4
Nuremberg 4
Redwood City 4
Shanghai 4
Shenzhen 4
Zhengzhou 4
Amsterdam 3
Aracaju 3
Barretos 3
Bogotá 3
Brockport 3
Caloocan 3
Campinas 3
Diadema 3
Dubai 3
Frankfurt am Main 3
Hangzhou 3
Indaiatuba 3
Johannesburg 3
Joinville 3
Manaus 3
Mogi Mirim 3
Montreal 3
North Bergen 3
Totale 2.665
Salva come PNG Salva come JPEG
Nome #
Exosomal PD-L1 expression and dynamic changes of immune response associated cytokines as predictive biomarkers for immune checkpoint blockage with PD-1/PD-L1 inhibitors in advanced/metastatic non-small cell lung cancer 274
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 252
Immunotherapy use in patients with HIV and non-small-cell lung cancer: Current data 245
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 222
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases 194
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 191
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 184
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 180
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study. 179
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review 169
Liquid biopsy tracking of lung tumor evolutions over time 164
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 162
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer 161
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 156
How I treat ALK-positive non-small cell lung cancer 156
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy 155
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site 153
Impact of erlotinib on overall survival in non small cell lung cancer patients: is the post progression survival a new paradigm? 151
Impact of circulating microRNAs mir-22, mir-24 and mir-34a on response to pemetrexed in patients with non small cell lung cancer 146
1995PApplication of ESCAT and OncoKB scales in liquid biopsy (LB) in advanced NSCLC patients (pts): Is it feasible and reliable? 146
Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario 145
NSCLC and HER2: between lights and shadows 141
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 137
Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study 135
Acquired resistance in oncogene-addicted non-small-cell lung cancer 126
Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC 126
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation 125
Treatment option for small cell lung cancer: does lanreotide represent a new choice? 78
Re-treatment with gefitinib or treatment with erlotinib after gefitinib failure in responsive non small cell lung cancers: new strategies to overcome acquired resistance. 78
Totale 4.731
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.683
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.683
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022192 0 0 0 0 9 9 14 9 1 41 36 73
2022/2023533 38 56 19 44 35 48 7 45 221 3 12 5
2023/2024149 8 25 8 9 12 60 2 10 1 1 0 13
2024/2025637 3 5 7 36 60 18 52 155 125 28 45 103
2025/20261.987 102 110 127 112 160 393 255 283 285 84 24 52
2026/2027365 26 166 68 100 5 0 0 0 0 0 0 0
Totale 4.731